. "Appendix L: Prospects for Immunizing Against Neisseria gonorrhoeae." New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States. Washington, DC: The National Academies Press, 1985.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
New Vaccine Development Establishing Priorities, Volume I: Diseases of Importance in the United States
Institutes of Health, Pub. No. 81–2213. Washington, D.C.: U.S. Government Printing Office.
Noegel, A., and E.C.Gotschlich. 1983. Isolation of a high molecular weight polyphosphate from Neisseriagonorrhoeae. J. Exp. Med. 157(6):2049–2060.
Norqvist, A., J.Davies, L.Norlander, and S.Normark. 1978. The effect of iron starvation on the outer membrane protein composition of Neisseriagonorrhoeae. FEMS Microbiol. Lett. 4:71–75.
O’Hare, P.A., N.J.Fiumara, and W.M.McCormack. 1980. Pelvic inflammatory disease among women presenting to emergency rooms of hospitals in Massachusetts. Am. J. Obstet. Gynecol. 138(7):909–912.
Platt, R., P.A.Rice, and W.M.McCormack. 1983. Risk of acquiring gonorrhea and prevalance of abnormal adnexal findings among women recently exposed to gonorrhea. JAMA 250(23):3205–3209.
Plaut, A.G., J.V.Gilbert, M.S.Artenstein, and J.D.Capra. 1975. Neisseriagonorrhoeae and Neisseriameningitidis: extracellular enzyme cleaves human immunoglobulin A. Science 190:1103–1105.
Rendtorff, R.C., J.W.Curran, R.W.Chandler, W.L.Wiser, and H.Robinson. 1974. Economic consequences of gonorrhea in women: experience from an urban hospital. J. Am. Vener. Dis. Assoc. 1(1):40–47.
Richardson, W.P., and J.C.Sadoff. 1977. Production of a capsule by Neisseriagonorrhoeae. Infect. Immun. 15(2):663–664.
Sadoff, J.C. 1984. Personal communication, Uniformed Services University of the Health Sciences, Bethesda, Md.
Schoolnik G.K., J.Y.Tai, and E.C.Gotschlich. 1983. A pilus peptide vaccine for the prevention of gonorrhea. Progr. Allergy 33:314–331.
Siegel, M., D.Olsen, C.Critchlow, and T.M.Buchanan. 1982. Gonococcal pili: safety and immunogenicity in humans and antibody function in vitro. J. Infect. Dis. 145(3):300–310.
Tramont, E.C. 1977. Inhibition of adherence of Neisseriagonorrhoeae by human genital secretions. J. Clin. Invest. 59:117–124.
Tramont, E.C., and C.C.Brinton. 1984. Clinical evaluation and laboratory evaluation of gonococcal pili. Presented at a conference on Ontogeny of Immune Function and Pathogenic Mechanisms Involved in Bacterial Vaccine Development, Sept. 17–20, 1984, National Institutes of Health, Bethesda, Md.
Tramont, E.C., J.Ciak, J.Boslego, D.G.McChesney, C.C.Brinton, and W.Zollinger. 1980. Antigenic specificity of antibodies in vaginal secretions during infection with Neisseriagonorrhoeae. J. Infect. Dis. 142(1):23–31.
Tramont, E.C., J.C.Sadoff, J.W.Boslego, J.Ciak, D.McChesney, C.C. Brinton, S.Wood, and E.Takafuji. 1981. Gonococcal pilus vaccine: studies of antigenicity and inhibition of attachment. J. Clin. Invest. 68(4):881–888.
Washington, A.E., W.Cates, Jr., and A.A.Zaidi. 1984. Hospitalizations for pelvic inflammatory disease. Epidemiology and trends in the United States, 1975–1981. JAMA 251(19):2529–2533.
Wiesner, P.J., and S.E.Thompson, III. 1982. Gonococcal infections. Pp. 235–257 in Bacterial Infections of Humans, A.S.Evans and H.A. Feldman, eds. New York: Plenum.